New Zealand markets closed
  • NZX 50

    11,235.72
    -7.57 (-0.07%)
     
  • NZD/USD

    0.5908
    -0.0043 (-0.71%)
     
  • ALL ORDS

    7,136.50
    -99.00 (-1.37%)
     
  • OIL

    88.04
    -0.78 (-0.88%)
     
  • GOLD

    1,835.60
    -11.60 (-0.63%)
     

Here's How Moderna Plans to Win in the Post-Emergency COVID Vaccine Market

Here's How Moderna Plans to Win in the Post-Emergency COVID Vaccine Market

High demand for coronavirus vaccines earlier in the pandemic pushed Moderna's (NASDAQ: MRNA) earnings into the stratosphere. In fact, Moderna could continue to generate billions in revenues annually from its first -- and so far, only -- approved product. For example, Moderna sold its vaccine to the U.S. government for about $26 a dose.